India Pharma Outlook Team | Thursday, 18 September 2025
Bayer announced the launch of Bayer Co.Lab AdVenture, a major extension of their global life sciences incubator network meant to connect biotechnological startups with vanguard venture capital firms worldwide. The shared goals of the platform include accelerating the access to financing, providing strategic guidance and global investment expertise, supporting early-stage companies in converting their groundbreaking ideas into healthcare solutions that makes a difference.
The launch is also the first anniversary of Bayer Co.Lab Shanghai where two Chinese biotech startups, OTR Therapeutics and Nutshell Therapeutics, have joined the innovation community. Both companies are engaged in state-of-the-art therapies which are in accordance with Bayer’s strategic priorities, thus showing the two companies’ mutual commitment to working on the areas of extremely high medical needs.
“Collaborations play a very vital role in bringing the pharmaceutical industry to a higher level of innovation,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing, Bayer Pharmaceuticals Division. “Bayer Co.Lab AdVenture is the biotech community booster as it offers global programs and investors easy access to resources that are ideal for startups growth and solve global challenges at a faster pace.”
Also Read: Max Healthcare, Medtronic Open Advanced Surgical Skill Lab
Bayer Co.Lab AdVenture is one of the great examples depicting Bayer’s open innovation approach and consequently is another testament to Bayer’s continuous efforts to stimulating biotech ecosystems that are already fairly unsettled by scientific research activities and to reinforcing global partnerships that can help solve the problems faced by the healthcare industry.
